<DOC>
	<DOCNO>NCT00000979</DOCNO>
	<brief_summary>To compare effectiveness toxicity didanosine ( ddI ) zidovudine ( AZT ) patient AIDS , advance AIDS-related complex ( ARC ) , asymptomatic infection CD4 count &lt; 200 cells/mm3 . AZT effective reduce mortality patient AIDS receive drug first episode Pneumocystis carinii pneumonia ( PCP ) patient advanced ARC . However , AZT therapy associate significant toxicity . In addition , effectiveness AZT appear decrease second third year therapy . For reason , development alternative therapy would least effective less toxic great importance . The drug ddI antiviral agent inhibits replication ( reproduction ) HIV le apparent toxicity AZT .</brief_summary>
	<brief_title>Comparison ddI Versus Zidovudine HIV-Infected Patients</brief_title>
	<detailed_description>AZT effective reduce mortality patient AIDS receive drug first episode Pneumocystis carinii pneumonia ( PCP ) patient advanced ARC . However , AZT therapy associate significant toxicity . In addition , effectiveness AZT appear decrease second third year therapy . For reason , development alternative therapy would least effective less toxic great importance . The drug ddI antiviral agent inhibits replication ( reproduction ) HIV le apparent toxicity AZT . AMENDED : 9/28/90 Patients assign one 2 treatment double-blind , randomly allocate , experimental design duration prior AZT therapy 0 16 week . ( Patients enter 16 week prior AZT randomize ddI continue dose level , adjust weight , follow originally plan . ) Patients assign one 3 treatment explain prior amendment duration prior AZT therapy great 16 week . Original design : Patients assign one three treatment double-blind randomly allocate experimental design . ddI administer two dose level . It anticipate patient see outpatient every 2 week first 4 week study monthly thereafter . This study continue least 18 month entry first subject .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Aerosolized pentamidine ( 300 mg every 4 week use Respirgard II nebulizer ) . In event physiological intolerance , alternative prophylaxis may : Trimethoprim / sulfamethoxazole 1 DS tab per day dapsone 50 100 mg/day . Allowed : Maintenance therapy active AIDS defining opportunistic infection patient 9 47 week ' experience zidovudine ( AZT ) . Treatment opportunistic infection sulfonamide contain drug : Pyrimethamine sulfadiazine clindamycin suppression toxoplasmosis acquire study entry ; fluconazole amphotericin B suppression cryptococcosis ketoconazole candidiasis . Intravenous acyclovir 10 day . Erythropoietin patient relevant treatment IND . Analgesics , antihistamine , antiemetic , antidiarrheal agent symptomatic therapy toxicity . Isoniazid ( INH ) acceptable therapy available . Metronidazole may use single course therapy exceed 14 day within consecutive 90 day interval . Note : Ketoconazole dapsone take 2 hour 2 hour take ddI ( amendment 5/20/91 ) . Concurrent Treatment : Allowed : Blood transfusion hemoglobin toxicity . Patients must : Have diagnosis AIDS advance AIDS relate complex ( ARC ) , per 8/09/90 amendment , asymptomatic HIV infection CD4 count = &lt; 200 cells/mm3 . Be either naive zidovudine ( AZT ) take AZT = &lt; 48 week . Have end treatment acute Pneumocystis carinii pneumonia ( PCP ) least 2 week study entry . For patient 2 month less experience AZT , PCP infection single AIDSdefining infection must within 120 day study entry . Per amendment , AIDSdefining condition allow 8 week prior study entry ( patient AZT stratum ) .Only one episode PCP permit unless patient &gt; 2 month AZT experience case &gt; 1 prior episode PCP infection allow . Not experienced major intolerance AZT dose least 500 mg patient AZT therapy = &lt; 48 week . A major intolerance define recurrent grade 3 great toxicity result discontinuation drug . Allowed : Basal cell carcinoma . In situ carcinoma cervix . Occasional premature atrial ventricular contraction . Patients develop new opportunistic infection study entry remain protocol . Patients whose AIDSdefining condition Kaposi 's sarcoma alone must CD4 cell count &lt; 300 cells/mm3 . Prior Medication : Allowed : Previous treatment zidovudine ( AZT ) 48 week . Exclusion Criteria Coexisting Condition : Patients follow symptoms disease exclude : Kaposi 's sarcoma ( KS ) evidence visceral disease KS require chemotherapy ; subject localize KS CD4 count = &gt; 200 cells/mm3 . AIDSdementia complex = &gt; stage 2 . Prior history acute pancreatitis within past 2 year chronic pancreatitis . Intractable diarrhea . History seizure within past 6 month currently require anticonvulsant control . History past current heart disease . Presence malignancy likely investigator opinion require cytotoxic myelosuppressive chemotherapy expect course trial . Concurrent Medication : Excluded : Oral acidify agent . Neurotoxic drug . NOTE : If patient require therapy PCP IV pentamidine , study mediation stop . Patients follow exclude : Active AIDS defining event . Maintenance therapy prior AIDSdefining opportunistic infection permit . Intolerance AZT dose 500 mg recurrent grade 3 toxicity great resulted discontinuation drug . Neoplasms specifically allow . Previous enrollment study ddI , ddC d4T . &gt; 48 week AZT therapy . An opportunistic infection adequately control suppressive therapy allow protocol . Psychological emotional problem sufficient , investigator 's opinion , prevent adequate compliance study therapy . Life expectancy = &lt; 6 month . Prior Medication : Excluded : Ganciclovir . AZT = &gt; 48 week . Excluded within 14 day study entry : Erythropoietin ( Eprex ) . Excluded within 30 day study entry : AntiHIV therapy AZT . Biologic response modifier . Other investigational drug . Corticosteroids . Neurotoxic drug . Excluded within 90 day study entry : Ribavirin . Prior Treatment : Excluded within 14 day study entry : Transfusion . Active alcohol drug abuse sufficient , investigator 's opinion , prevent adequate compliance study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2003</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Zidovudine</keyword>
</DOC>